Romosozumab efficacy on fracture outcomes is greater in patients at high baseline fracture risk: a post hoc analysis of the first year of the frame study.

Eugene V McCloskeyH JohanssonN C HarveyM LorentzonY ShiJ A Kanis

Published in: Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA (2021)

Efficacy of romosozumab on clinical fracture, osteoporotic fracture, and MOF is significantly greater in patients at high baseline fracture risk compared with placebo.

Keyphrases

hip fracture
randomized controlled trial
clinical trial
type diabetes
bone mineral density
open label